Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.
Moreau P et al.Drugs. 2016 May;76(8):853-67. doi: 10.1007/s40265-016-0573-4.

Clinical use and applications of histone deacetylase inhibitors in multiple myeloma.
Tandon N et al. Clin Pharmacol. 2016 May 6;8:35-44. doi: 10.2147/CPAA.S94021. eCollection 2016.

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.
Usmani SZ et al. Blood. 2016 May 23. pii: blood-2016-03-705210. [Epub ahead of print].

Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.
Moreau P et al. Drugs. 2016 May 20. [Epub ahead of print].

A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.
Gupta N et al. Br J Haematol. 2016 May 16. doi: 10.1111/bjh.14125. [Epub ahead of print].

CHAMPION-1: a phase 1/2 study of weekly carfilzomib and dexamethasone for relapsed or relapsed and refractory multiple myeloma.
Berenson JR et al. Blood. 2016 May 12. pii: blood-2015-11-683854. [Epub ahead of print].

The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma.
Brown S et al. BMC Hematol. 2016 May 17;16:14. doi: 10.1186/s12878-016-0053-9. eCollection 2016.

Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Paviglianiti A et al. Haematologica. 2016 May 26. pii: haematol.2015.138917. [Epub ahead of print].

Carfilzomib (Kyprolis): A Novel Proteasome Inhibitor for Relapsed And/or Refractory Multiple Myeloma.
Perel G et al. P T. 2016 May;41(5):303-7.

Panobinostat (Farydak): A Novel Option for the Treatment of Relapsed Or Relapsed and Refractory Multiple Myeloma.
Moore D et al. P T. 2016 May;41(5):296-300.

Ixazomib for multiple myeloma.
Burki TK et al. Lancet Oncol. 2016 May 6. pii: S1470-2045(16)30131-0. doi: 10.1016/S1470-2045(16)30131-0. [Epub ahead of print].